Akynzeo

DRUG3 trials

Sponsors

Christina Ruhlmann, VIFORFRANCE, Simon Williamson Clinic

Conditions

Adverse EventCervical CancerChemotherapy Induced Nausea and VomitingChemotherapy-induced Nausea and VomitingOncology

Phase 2

Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin

Christina RuhlmannAdverse Event, Cervical Cancer, Chemotherapy-induced Nausea and Vomiting

Start: 2018-09-05End: 2023-04-15Target: 80Updated: 2021-12-14

Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy

Simon Williamson ClinicChemotherapy Induced Nausea and Vomiting

Start: 2023-09-09End: 2023-12-31Target: 100Updated: 2023-10-10

Phase 4

Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients

VIFORFRANCEOncology

Start: 2018-09-19End: 2019-07-31Target: 426Updated: 2019-02-06

Related Papers

Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy—the DANGER-emesis study

Supportive Care in Cancer2025-05-28

NEPA <scp>(</scp>Netupitant/Palonosetron) for the Prevention of Chemotherapy‐Induced Nausea and Vomiting (<scp>CINV</scp>) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough <scp>CINV</scp> in Cycle 1 of Chemotherapy: A Phase <scp>II</scp> Clinical Trial

Cancer Medicine2025-03-27